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Abstract: Hepatitis B virus (HBV) is a major focus of antiviral research worldwide. The International
Coalition to Eliminate HBV, together with the World Health Organisation (WHO), have prioritised
the search for a cure, with the goal of eliminating deaths from viral hepatitis by 2030. We present
here a comprehensive model of intracellular HBV infection dynamics that includes all molecular
processes currently targeted by drugs and agrees well with the observed outcomes of several clinical
studies. The model reveals previously unsuspected kinetic behaviour in the formation of sub-viral
particles, which could lead to a better understanding of the immune responses to infection. It also
enables rapid comparative assessment of the impact of different treatment options and their potential
synergies as combination therapies. A comparison of available and currently developed treatment
options reveals that combinations of multiple capsid assembly inhibitors perform best.
Keywords: hepatitis B virus; intracellular model; antiviral therapy; packaging signal; virus assembly
1. Introduction
The hepatitis B virus is a major global health burden. According to the Hepatitis
B Foundation, ∼2 billion people have been infected with the hepatitis B virus (HBV),
resulting in ∼292 million chronic infections that lead to ∼884,000 deaths each year from
virally related complications, such as liver cancer and cirrhosis. Despite the availability
of an excellent prophylactic recombinant vaccine, ∼30 million people will become newly
infected each year [1]. The vaccine is not curative, and infected individuals are currently
treated with drugs targeting the viral polymerase. These come with a risk of eliciting
resistance mutations, even, in some cases, within months of starting therapy [2]. Clearing
the virus from patients is currently prevented because of the persistence of a covalently
closed circular DNA (cccDNA) episome of the viral genome, which acts as a source of
novel virus formation. Achieving the goal of eliminating viral hepatitis as a major public
health threat by 2030 will require a systematic evaluation of existing therapeutic options
and novel forms of antiviral therapy, both current and yet to be discovered, including the
potential synergies of combination therapies [3].
The in silico approach presented here is designed to support these efforts. Based on
the current understanding of the HBV intracellular lifecycle, we developed a mathematical
model grounded in experiments that permits rapid and cheap evaluation of antiviral drug
strategies. This is particularly important because success in meeting the global challenge
may require targeting multiple aspects of the viral lifecycle with potentially unexpected
synergistic effects. Whilst some aspects of intracellular HBV dynamics have been modelled
previously [4–6], our model is the first that takes into account reactions describing all
the processes targeted by different types of antiviral strategies [3,7], including details of
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the assembly of both infectious and non-infectious particles and the mechanism of nu-
cleocapsid assembly [8]. In particular, the model includes the formation of the sub-viral
particles (SVPs) that vastly outnumber infectious virions. The model is based on a Gillespie
algorithm and reaction networks. It can therefore capture the kinetics of particle formation
at the low molecular species concentrations typical at the start of an infection. This reveals
unsuspected features in SVP dynamics that could play important roles for immune recog-
nition [9,10]. We also demonstrate that the model correctly captures experimental/clinical
outcomes in a comparative analysis of licensed HBV drugs, and provides an assessment
for drug options that are currently in the developmental phase. Among others, our results
reveal significant synergistic effects between capsid assembly modulators (CAMs) that
are already being developed and gRNA packaging signal (PS)-targeting drugs that we are
developing, suggesting novel forms of combination therapy.
2. Materials and Methods
2.1. An In Silico Model of Intracellular HBV Infection Dynamics
We have developed a comprehensive stochastic model for intracellular dynamics of
HBV infection. The model consists of essential steps of the viral life cycle, which are shown
in Figure 1. Similarly to intracellular models of hepatitis C virus [11], in this model, the viral
entry step (Step 0; Figure 1), in which the virus releases its nucleocapsid (rcNC) into the
cell through the sodium taurocholate cotransporting polypeptide (NTCP) receptor [12],
is not included explicitly, as our focus is on the intracellular infection dynamics. We use our
model to study the virion release kinetics from a single infected cell in unprecedented detail,
and to present a model in which to test antiviral strategies and explore their synergies.
We have used discrete reaction networks to develop our model, rather than continuous
equations, enabling detailed study of the onset of the infection when particle numbers
are low. The model and its advantages over previous models are described briefly in the
following. A comprehensive account of the model, including all reactions and parameter
choices, is provided in the Supplementary Material.
cccDNA production: The first step after viral entry is the formation of cccDNA (Step 1;
Figure 1). Murray and Goyal [6] have studied cccDNA formation in their model, which in-
cludes delivery of cccDNA by the nucleocapsid to the nucleus. In their model, a stochastic
agent-based approach using anordinary differential equation (ODE), this step is repre-
sented as a single reaction, describing the net result of three discrete reactions (Step 1;
Figure 1) that we are modelling here. Firstly, there is the intracellular trafficking where
the rcNC moves toward the nucleus. Secondly, the rcNC releases its cargo, which is a
relaxed circular DNA (rcDNA), into the nucleus [13]. We assume that these two reactions
occur as one reaction with rate α. Then, the rcDNA is converted into cccDNA (at rate a).
This conversion occurs via cellular enzymes that are normally involved in base excision
repair of DNA damage [9,14] akin to correction of “damaged” DNA. Splitting this step
into two reactions is important because capsid assembly modulators (CAMs) can bind to
the rcNC and disassemble it [15]. In addition, using anti-host DNA repair factors, which
is presented as a possible future treatment [7], will suppress the last reaction of this step.
Therefore, we used two reactions for these steps, enabling us to study the impact of the
two treatment options, and present a comparison between them.
Epigenetics of cccDNA: cccDNA is organised into mini-chromosomes with host cell histones
and potentially other host and viral proteins [16,17]. Therefore, transcription from cccDNA is
subject to epigenetic regulation, providing numerous options for dynamic epigenetic control
of cccDNA transcriptional activity [18–20]. In the absence of the X protein (HBx), which gets
produced by the cccDNA over the course of the infection, cccDNA appears to be rapidly
silenced [21]. In addition, HBx promotes the de-silencing of cccDNA [7] (Step 2; Figure 1).
We model (de-)silencing of cccDNA with rate (λo f f /(1 + sX)) λon(1+ sX), where s indicates
the efficiency of the available numbers of HBx proteins (X) [22]. This step is not included
in previous models. However, targeting the X protein to keep the cccDNA silenced is
suggested as a possible therapeutic strategy [7], and it is therefore included in our model.
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Figure 1. The hepatitis B virus (HBV) life cycle.Step 0: Viral entry is mediated by the sodium-
taurocholate co-transporting polypeptide (NTCP) receptor, which allows the nucleocapsid (rcNC)
containing relaxed circular DNA (rcDNA) to be released into the cell via endocytosis. This step is
not included explicitly in the model. Step 1: After attachment of the rcNC to the nucleus, it delivers
the rcDNA. The host DNA repair factors convert the rcDNA into covalently closed circular DNA
(cccDNA). Step 2: X protein, which gets produced by the cccDNA over the course of infection,
promotes the de-silencing of the cccDNA and blocks its silencing. Step 3: The cccDNA is used as
a template by RNA polymerase II (RNA Pol II) to synthesise viral RNAs, including the pgRNA;
LS, S, PreC, and X mRNAs. The pgRNA encodes both the core (C) and polymerase (P) proteins;
X mRNA the X protein; LS mRNA the L surface protein; S mRNA the M and S surface proteins;
and PreC mRNA the precore (PreC) protein. Step 4: Translation of these mRNAs by ribosomes (Rib)
leads to synthesis of viral proteins. Step 5: The pgRNA and P form a 1:1 ribonucleoprotein (RNP)
complex, which is assembly competent. Step 6a: Encapsidation of the RNP complex by C proteins to
form a nucleocapsid containing pgRNA:P (pgNC), also termed the immature nucleocapsid. Step 6b:
Assembly of C proteins into an empty nucleocapsid (emNC). Step 7: The reverse transcription
of pgRNA by P within the pgNC resulting in the conversion of pgNC into an rcDNA-containing
nucleocapsid (rcNC), which is also termed the mature nucleocapsid. Step 8: Recycling of the rcDNA
from mature nucleocapsids to form more cccDNAs. Step 9a: Envelopment of mature nucleocapsids
within a membrane layer containing the surface proteins L, M, and S, leading to the secretion of a
complete virion. Step 9b: Envelopment of an immature nucleocapsid resulting in secretion of an
RNA-containing particle. Step 9c: Envelopment of an empty nucleocapsid and secretion of an empty
virion. Step 9d: L, M, and S proteins form empty filaments and filamentous subviral particles (SVPs)
via conventional tubular budding into late endosomes and exit the cell. Step 9e: S proteins assemble
into octahedral spheres (spherical SVP) and exit the cell.
Transcription of cccDNA: cccDNA serves as a template for transcription via host RNA
polymerase II (Step 3; Figure 1), producing: pregenomic RNA (pgRNA; also called the
C (core) mRNA [23]) coding for core (C) and polymerase (P) proteins; X mRNA coding
for the X protein; LS mRNA coding for the L surface protein; S mRNA coding for the M
and S surface proteins; and PreC mRNA coding for the precore protein, which forms E
protein (HBeAg). Clinically, measuring the level of HBeAg can be used as an indicator
for the phases of chronic infection, which could be included in a within-host model [24].
However, as we are focusing on the formation of new particles over the infection of a single
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cell and HBeAg is a non-structural protein, it is not included in the simulation results.
Nakabayashi [4,5] includes this step in his model, covering only pgRNA and S mRNA
production from cccDNA. However, the inclusion of all viral mRNA species in the model
is important due to the roles of their products in the viral life cycle, such as X protein in
the activation of cccDNA, or the surface proteins in the envelopment of nucleocapsids.
We therefore model transcription by two sets of five reactions, describing complex for-
mation between cccDNA and RNA polymerase II, followed by mRNA production and
cccDNA release from the complex (Supplementary Equation (S1)) [25]. In this way, we can
capture the delay of this process for the production of each RNA, and we can study the
impact of the number of RNA polymerase II (RNA Pol II) molecules on virus dynamics.
RNA Pol II and cccDNA bind together at rate b to produce pgRNA. Since the level of
surface protein is higher than the HBV DNA level, we assume the binding rates that lead
to the production of the LS and S mRNAs to be nLd times larger [6].
Viral protein synthesis: After export from the nucleus to the cytoplasm, the viral mRNAs
are translated (Step 4; Figure 1) by ribosomes. This is modelled by analogy to the transcrip-
tion step (Supplementary Equation (S2)) and has similar advantages [25]. Ribosome and
pgRNA bind at rate d to produce polymerase (P) protein.
rcDNA-containing nucleocapsid formation: This process contains three steps: Firstly, P pro-
tein and pgRNA form a ribonucleoprotein (RNP) complex (Step 5; Figure 1) [13,23,26]. This is
mediated by a short structured RNA signal located at the 5′ end of the pgRNA, called ε,
that is recognised specifically by P [27–30]. Secondly, nucleocapsid assembly from core
(C) protein dimer occurs around the RNP complex (Step 6a; Figure 1) [8]. Then, the
reverse transcription step occurs (Step 7; Figure 1), resulting in the formation of an rcDNA-
containing nucleocapsid (mature nucleocapsid; rcNC) [23]. For the formation of rcNCs,
Nakabayashi [4,5] considered just two of these reactions, corresponding to the formation
of RNP from P and pgRNA and of rcNC from core protein and RNP. Murray and Goyal [6]
only considered one of these reactions, the production of rcNCs from cccDNA, as a linear
function. However, the formation of a nucleocapsid around the RNP complex is promoted
by at least three packaging signals (PSs; denoted as PS1, PS2, and PS3) in the pgRNA,
which bind to the core protein (CP) dimer [8], as illustrated in Figure 3a. A number of
small-molecular-weight compounds have been identified that can bind to these three PSs,
inhibiting nucleocapsid assembly in vitro. In addition, CAMs can bind to C proteins
and thus alter the kinetics and pathway of C protein assembly [15]. In order to be able
to study the impact of these nucleocapsid assembly inhibitors and compare their action,
we included unprecedented details of the assembly process in our model. Moreover, in
addition to complete virions (infectious particles), an infected cell produces incomplete
particles (fully formed particles without a DNA genome). Incomplete particles occur in
three distinct forms: RNA-containing particles; empty virions; and subviral particles (SVPs)
[23]. SVPs assemble from surface proteins (L, M, and S) only, and are either filamentous
or spherical with diameters of about 20 nm [31,32]. Incomplete particles deplete the re-
sources and can act as decoys for the immune response [10]. Therefore, modelling their
assembly and revealing their release kinetics are important. The modelling of these steps is
described below:
We model the formation of the RNP complex, which is the basis for nucleocapsid
assembly, with rate g.The assembly step (Step 6a; Figure 1) is promoted by three PSs.
We assume that CP dimer binding to PSs contributes to the formation of a nucleation
complex;Figure 3b shows all possible pathways for this, where R denotes the RNP complex
and Cj (j = 1, 2, 3) indicate PSj bound to a CP dimer. Reactions between complexes in which
different combinations of these PSs are bound are shown as black arrows, representing
the binding/unbinding of CP (Figure 3b). Once all PSs are bound to CP, that is, when the
RC1C2C3 complex is formed, more CP dimers (denoted as C) are recruited to build the
fully formed pgRNA-containing nucleocapsid (pgNC), which is also called the immature
nucleocapsid. In our model, we assume that nucleocapsids are made of 120 C proteins
following a T = 4 architecture, ignoring the T = 3 particles that occur in only 5% of
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cases [8]. Thus, we consider 117 reactions, describing the binding of individual C proteins
to the RC1C2C3 complex to create the pgNC. At this stage, the pgRNA serves as a template
for the reverse transcription reaction, leading to the formation of rcDNA with rate s1 (Step 7;
Figure 1), and ultimately to assembly of the rcDNA-containing mature nucleocapsid (rcNC).
In ∼10% of immature nucleocapsids, the reverse transcription leads to the synthe-
sis of a double-stranded linear DNA (dslDNA) that can be integrated into the host cell
genome, where it acts as a template for LS mRNA, S mRNA, and X mRNA. We note that
dslDNA can also be circularised via the non-homologous end-joining (NHEJ) DNA repair
pathway [33,34]. However, we do not integrate dslDNAs into the model and only consider
rcDNAs because the production rate of dslDNA is much lower than that of rcDNA. Inte-
gration of dslDNA occurs approximately once per ∼105 − 106 infected cells [35], and many
cccDNAs produced from dslDNA are functionally defective, as the NHEJ pathway is
error-prone [7].
Envelopment and secretion of complete and incomplete particles: At low L protein levels,
the rcNC can deliver its contents to the nucleus to amplify the cccDNA reservoir (Step 8;
Figure 1) [6]. By contrast, when the level of L protein is sufficiently high, rcNCs acquire
the viral surface proteins (L, M, and S) and exit the cell via the cellular secretory pathway
(Step 9a; Figure 1) [13,36]. In order to reflect this dependence on the level of L protein,
the delivery of the rcNCs’ content to the nucleus is modelled at rate te−λL (Supplementary
Equation (S3)), whilst the rcNC release rate is t(1− e−λL) [6,37]. Moreover, since a complete
virion collects the surface proteins during budding, we consider its secretion as a single
reaction in the model:
rcNC + 80S + 20M + 20L
t(1−e−λL)
−−−−−−→ complete virion . (1)
The protein stoichiometry has been chosen at a relative ratio of 1:1:4 for L, M, and S as
in the filamentous SVPs [38], as they are secreted from the same compartment [39]. Given
that about 210 to 270 surface protein subunits have been reported per viral particle [31,40],
and that both core and surface proteins occur as dimers [41], we assume a 1:1 stoichiometry
between the core and the surface proteins, resulting in the ratio 20:20:80 for L, M, and S.
Secretion of RNA-containing particles occurs at low levels. These particles are immature
nucleocapsids that have not undergone the reverse transcription step, but still acquire the vi-
ral surface proteins and exit the cell [3,23,42–45] (Step 9b; Figure 1). Moreover, 120 C proteins
can assemble into empty nucleocapsids (Step 6b; Figure 1) [46,47] and exit the cell as empty
virions. Filamentous SVPs, also called L-rich subvirals [41], are formed via conventional
tubular budding [39,48] upon release. The secretion of all these particles is modelled akin to
that of complete virions (Supplementary Equations (S4)–(S6)). However, secretion of spher-
ical SVPs (octahedral particles made of 48 S proteins) has a different pathway: S proteins
attached to the membrane of the endoplasmic reticulum (ER) self-assemble into filaments
with diameters of about 20 nm [41]. These filaments are transported to the roughER–Golgi
intermediate compartment (ERGIC), where they convert into spheres before exiting the
cell (Step 9e; Figure 1) [32,41,49]. In the model, we assume that as soon as 48 S proteins
are assembled, they are released as a spherical particle at rate t2. It has also been reported
that the production and release of spherical versus filamentous particles depends on the
concentration of L protein, with lower values favouring spherical SVPs [37,39,50]; this impact
of the L protein is captured in the initiation reaction (Supplementary Equation (S7)).
2.2. Modelling of Different Drug Treatments
Figure 2 shows all currently available and possible future treatment options for chronic
hepatitis B [3,7]. Since our comprehensive model covers all reactions that can be targeted
by these drugs, we can study their effects and explore synergies. The impact of these drugs
is modelled as follows.
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Figure 2. Current and potential future drugs for the treatment of HBV. The different types of drugs
are labelled next to the viral life cycle steps they target. Capsid assembly modulators (CAMs) both
inhibit nucleocapsid assembly and promote disassembly of mature nucleocapsids, either following
entry or prior to release, and are therefore indicated at multiple steps of the viral life cycle. Interferon
(IFN)-based therapy blocks the transcription step. Small interfering RNAs (siRNAs), which reduce
mRNA levels, are indicated by the bar-headed line. Geldanamycin (GA) prevents the formation
of the ribonucleoprotein (RNP) complex. Nucleot(s)ide analogues (NAs) inhibit the progression of
immature into mature nucleocapsids. Packaging signal (PS)-targeting drugs bind to the PSs of HBV
and inhibit nucleocapsid assembly. Inhibitors of HBsAg release target viral and subviral particle
(SVP) egress.
Interferon (IFN)-based therapy comprises stand-alone IFN-α orpegylated interferon-
α (Peg-IFN-α) [51]. IFN-α results in cccDNA-bound histone hypoacetylation as well as
active recruitment of transcriptional corepressors to the cccDNA and reduces binding of
transcription factors to an active cccDNA [19]. It also degrades cccDNA via the activation
of APOBEC3A in infected cells [52–54]. Thus, we model the action of IFN-α binding as










Here, IFN denotes the amount of IFN-α, ψ is the efficacy of this drug in cccDNA
degradation, and Ibind and Iunbind are the binding and unbinding rates of IFN-α, respectively.
Note that IFN-α also acts via the activation of natural killer (NK)/NKT cells, but these effects
must be studied in an intercellular model. However, this treatment option is associated
with significant side effects [55,56].
Geldanamycin (GA) prevents the formation of the RNP complex [26], mediated by
its binding to heat shock protein 90 (Hsp90) [57–59], which is required for association of P
with the pgRNA. Assuming that Hsp90 is not rate limiting, we model the formation of a
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where kbind and kunbind indicate the binding and unbinding rates of GA.
Nucleot(s)ide analogues (NAs), such as lamivudine, adefovir, entecavir, tenofovir,
telbivudine, famciclovir, and clevudine [51], incorporate into growing DNA strands and
thus inhibit the progression from immature to mature nucleocapsids [3,7]. This is modelled










where lbind and lunbind are the binding and unbinding rates of NAs to pgNC.
A further class of drugs is that of virus assembly inhibitors, which target core pro-
tein assembly. Capsid assembly modulators (CAMs), also called core protein allosteric
modulators (CpAMs), bind to C protein and thus alter the kinetics and pathway of C
protein assembly [15,60]. This either leads to the formation of morphologically intact
empty nucleocapsids (class I mechanism of action (MoA) compounds), or to aberrant
nucleocapsids devoid of pgRNA (class II MoA compounds) [61]. These drugs can also
inhibit the formation of cccDNA due to an accelerated breakdown of nucleocapsids in the
cytoplasm [62,63]. It has been shown that elongation of positive-stranded DNA induces
structural changes in the nucleocapsid that cause mature nucleocapsids to bind CAMs,
triggering their disassembly [15]. Moreover, CAMs efficiently inhibit the replication of
HBV mutants resistant to NAs [64,65] and are active against multiple HBV genotypes [61].
Several CAMs are in preclinical evaluations or have entered clinical trials. Lahlali et al. [63]
have studied the impact of the novel CAMs JNJ-827 and JNJ-890, which are class I and II,
respectively, and are potent inhibitors of HBV replication with respective half-maximal
effective concentrations of 4.7 and 66 nM, respectively.






where (Cunbind)Cbind are the (un)binding rates. Moreover, C:CAM complexes can associate
to form empty nucleocapsids. As JNJ-827, which is class I, has a much lowerEC50 (the
concentration of a drug that gives half-maximal response), we only model the class I
scenario. C:CAM complexes form morphologically intact nucleocapsids requiring 120 units.
We model the formation and secretion of empty nucleocapsids as:
C:CAM + jC:CAM
κnc
−→ (j+1)C:CAM, j = 1, . . . , (nuc − 1),
C:CAM + jC:CAM
κ1




emNC:CAM + 80S + 20M + 20L
t(1−e−λL)
−−−−−−→ empty virion,
where nuc is the number of core proteins in the nucleation complex [46,66], and knc and κ1
are the forward rates for the nucleation and elongation reactions, respectively.
As suggested in [15], CAMs can also bind to rcNCs and trigger their disassembly,
followed by degradation of the rcDNA. We assume that dissociated nucleocapsids are par-
tially assembled; therefore, C protein in these intermediates is not available for formation
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where kdis indicates the disassembly rate.
In order to target the role of PSs in nucleocapsid formation, a number of small-
molecular-weight compounds have been identified that can bind to the three packaging
signals of HBV and inhibit nucleocapsid assembly in vitro. The impact of these novel nu-
cleocapsid assembly inhibitors is modelled via the (un)binding to PSs using experimentally
measured affinities (Supplementary Table S2), as described in detail in the Supplemen-
tary Material.
Novel therapeutic strategies: Novel, potentially curative therapies for HBV infection
are either evaluated in preclinical models or are in the first phases of clinical develop-
ment [3,7]. These include entry inhibitors that reduce the infection rate of target cells;
anti-host DNA repair factors that inhibit the conversion of rcDNA into cccDNA by tar-
geting the DNA repair factors; cccDNA and HBx protein targeting drugs that increase or
decrease the silencing and de-silencing rates of cccDNA, respectively; small interfering
RNAs (siRNAs) that create an RNA-induced silencing complex (RISC) with mRNAs and
cleave them; and inhibitors of viral and SVP release that target the viral and SVP egress.
Our detailed model of the HBV life cycle contains all reactions pertinent to the processes
targeted by these drugs, enabling a comparative analysis of these possible future treatment
options with the already available drugs.
3. Results
3.1. Novel Insights into Infection Kinetics in the Drug-Free Situation
The cumulative number of infectious and noninfectious particles released over time was
computed as an average over 100 stochastic simulations of the reaction network (Figure 3c)
using the Gillespie algorithm [67] implemented in Fortran and parameters adapted from
the experimental literature (Supplementary Table S1) [68]. We assume infected cells to
have a lifespan of approximately 600 h. This is an implicit way of accounting for the fact
that an infected cell is the target of innate and adaptive immune responses that reduce its
lifetime below that of the lifespan of the cccDNA of around 1200 h [6]. For parameters
not covered in the experimental literature, a sensitivity analysis was performed to ensure
that model outcomes are not biased by parameter choices (Supplementary Figures S1–S9).
Consistently with experimental results, the most abundant species are the spherical SVPs
(Figure 1 [31,49]) that are released prior to other particle types. They act as decoys binding
anti-HBV antibodies. Interestingly, their release profile shows a two-phase behaviour that
has not been reported before. When the first intact virions are released, after about 90 h
post-infection, the release of the SVPs stalls (see the Phase 1 plateau in Figure 3c) until the
onset of a second release phase (Phase 2 in Figure 3c). The latter phase coincides with a
drop in the concentration of L proteins within the cell (green dashed line in Figure 3c).
Additionally, during Phase 1, the level of S proteins in a complex decreases before we
observe the release of complete virions, as seen in Supplementary Figure S10. The length
of Phase 1 increases with the rate of particle release, λ (Figure 3d). Our sensitivity analysis
indicates that this two-phase behaviour is prevalent, except for small (<2 × 10−4) values
of λ. However, as λ impacts the number of cccDNAs formed (Figure 4a), these small
values of λ are associated with higher numbers of cccDNA per cell. cccDNA levels rarely
exceed one copy per cell [33], fixing λ > 2 × 10−4. For these values of λ, the model always
displays the two-phase behaviour (Figure 3d), suggesting that it is biologically significant.
In HBV/HIV coinfection, it has been observed that the number of cccDNAs can sometimes
be as high as 10–16 cccDNAs per cell [69] (although the median was still found to be one).
However, due to the complexity of these coinfections, this is beyond the scope of this model.
We know that empty virions are typically found at 100-fold higher levels than complete
virions [23]. Figure 3e indicates that although decreasing g increases the total number of
released complete virions, the ratio of the number of released empty virions over complete
virion falls below 100 (Figure 3f). Increasing g or decreasing d, have the same effects. Thus,
in our simulations, we assume d = 40 molecule−1 h−1 and g = 5 molecule−1 h−1, which
provides a more realistic viral dynamic.
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Figure 3. The release kinetics indicate a novel two-phase behaviour in the drug-free case. (a) The
interaction between PSs and C proteins where C proteins bind and unbind to the RNP (R) complex.
(b) All possible pathways to occupying all three PSs. (c) The time evolution of the model shows the
cumulative number of released particles, averaged over 100 simulations. The 95%CI (the confidence
interval, shown as shaded area around each curve) is included, but is not visible due to the small
size and the logarithmic scale. This can be seen more clearly in Figure 5 and Figure S11. Phase 1
is the plateau in the release of spherical SVPs. The average number of RNA-containing particles
released over 100 simulations is 0.1 (0.1 ± 0.07 95% CI), which is not visible here due to the scale,
but is shown in Figure S11d. Although L protein does not get released, its concentration is plotted
(green dashed line) to show the impact of L protein on the release of particles and the emergence
of Phase 1. (d) The length of Phase 1 as a function of λ and nLd (Supplementary Equations (S1) and
(S3)). (e) The total number of complete virions released from an infected cell over 600 h after cccDNA
formation. (f) The ratio of the number of empty virions over complete virions released over 600 h
after cccDNA formation as a function of g, which is the binding rate of P protein to pgRNA, and d,
which is the binding rate of the ribosome to the pgRNA (Supplementary Equation (S2)). This figure
is plotted using parameter values from Supplementary Table S1.
3.2. Modelling Synergies between Antiviral Strategies
Simultaneous modelling of the steps of a viral life cycle targeted by different drugs
permits assessment of their relative merits and synergies. For the two types of approved
anti-HBV therapy, i.e., interferon (IFN)-based therapy (IFN) and nucleot(s)ide analogues
(NAs), data on the clinical outcomes of therapy are available and can be used to validate
the model. The levels of HBeAg protein, an indicator of active viral replication, and the
HBV surface proteins (SVPs) are typically used as indicators of the severity of an infection.
Based on these measures, IFN has been reported to perform better than NAs, and no
synergistic effects between these two treatments were observed [2]. This is in excellent
agreement with our model (Figure 5a). Even when the NA concentration (based on
Tenofovir, the most efficient analogue) was set to five times that of IFN (using a free
concentration of 20 molecules for this drug, which was added once the first cccDNA was
formed), it still performed worse. The IFN+NA curve in Figure 5a shows the impact of
using a free concentration of 50 molecules of NA plus 10 molecules of IFN (adding half the
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concentration of each drug to the system), with no significant synergistic effects between
these drugs.
Figure 5 shows the impact of treatment options on the level of released complete
virions. Supplementary Figure S11 indicates their impact on the level of released incomplete
particles. This figure shows that IFN therapy, which targets the transcription process and
release inhibitors, blocks the budding process, can reduce the level of incomplete particles
in a single cell model slightly, but the other treatment options have no impact. However,
by blocking the formation of new complete virions, these treatments will reduce the level
of incomplete particles indirectly. The impact of this reduction could be studied in an
intercellular model of HBV infection.
Figure 4. Prediction of cccDNA amplification and revealing rcDNA delivery step as the most crucial
reaction in cccDNA formation. (a) The average number of cccDNAs in an infected cell as a function
of λ and nLd (Supplementary Equations (S1) and (S3)). The increase in the number of cccDNAs
happens due to the intracellular cccDNA amplification step (Step 8; Figure 1). (b) The probability of
prevention of cccDNA formation over 10,000 simulations after viral entry in a drug-free case. We
just consider the cccDNA formation step (Step 1; Figure 1) when one rcNC is entered into a cell.
Probability indicates the number of simulations where cccDNA did not get formed over 10,000. This
figure is plotted using parameter values from Supplementary Table S1.
Given the success of the model in capturing the relative merits of known treatment
options, we applied it to the additional antiviral therapies listed in [3] (Figure 2), which are
currently at different stages of development. These include: Cp-assembly-directed CAMs
(based on the most efficient variant (JNJ-827); HBsAg release inhibitors; and small inter-
fering RNAs (siRNAs). Details of the modelling and published binding affinities used are
given in the Supplementary Material, and results are shown in the context of virion concen-
tration in the absence of treatment (Control). For siRNAs, different choices of cleavage rates
and dissociation constants were explored (Supplementary Figure S7), assuming a binding
affinity of 0.1 nM, corresponding to the smallest value known for any of the existing drugs
to give this drug an advantage. We also chose a cleavage rate of 10 h−1; Supplementary
Figure S7 shows that increasing the cleavage rate above 10 h−1 does not have a significant
effect on the outcome for this drug. For release inhibitors, we assumed their efficacy to
be equal to 95%, as a generous assumption. Even under these conditions, these drugs are
outperformed by CAMs (Figure 5a). Geldanamycin (GA) is not included in the comparison,
as it performed significantly worse than the other drugs. Despite an initial delay in virion
release due to inhibition of P and pgRNA complex formation (Supplementary Figure S5a),
it resulted in an increase in the number of virions released (Figure 3e). Similarly, targeting
the HBx protein, which is presented as a possible future treatment option, does not appear
to be a promising strategy (note that decreasing b is not effective; see Supplementary
Figure S5). The assembly inhibitor CAM performs best, reducing the total number of
complete virions to ∼3% of the Control.
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Figure 5. Comparative analysis of all possible treatment options for HBV, revealing a synergistic
effect between nucleocapsid assembly inhibitors. (a) The dynamics of complete virions released with
different treatment options after cccDNA formation for treatment starting once the initial condition
cccDNA = 1 is reached in the model. A free concentration of 20 drug molecules is considered,
except for NA, which is set to 100, and for IFN+NA, with IFN = 10 and NA = 50 (half concentration
for each drug). Black shows the absence of treatment (Control) for comparison. (b) The dynamics of
complete virions released after adding different PS-targeting compounds. (c) Impact of CAMs on the
probability of prevention of cccDNA formation over 10,000 simulations after viral entry, starting with
the initial condition rcNC = 1. We only focus on the cccDNA formation step (Step 1; Figure 1) when
one rcNC has entered the cell. α is the delivery rate of rcDNA to the nucleus, and we assume that
the conversion rate of rcDNA to cccDNA is 1 h−1 (a = 1 h−1). (d) Synergistic effect between CAM
and compound 15 (C15), with treatment starting once the initial condition cccDNA = 1 is reached in
the model. The average number of released complete virions when the concentration of each drug
is equal to 10 molecules is shown for clarity. This figure is plotted using parameter values from
Supplementary Table S1.
Given the success of the NC assembly inhibitors, we explored an alternative strategy
to block its formation. Recently, a series of small-molecular-weight compounds that bind
to the three HBV PSs, inhibiting nucleocapsid assembly in vitro, have been identified.
We modelled their action via the (un)binding to PSs using the experimentally measured
affinities of these lead compounds for the three PSs (Supplementary Table S2). Figure 5b
shows a comparison: Compound 15 (C15) performs best and is comparable with the
outcome for the CAMs in Figure 5a. This compound binds with significant affinity to all
three PSs, whilst the next best compound (C21) binds strongly to PS1 but very weakly to all
others. This suggests that cooperativity between PSs in the pgRNA is important, making
drugs capable of binding tightly to several PSs simultaneously highly effective.
Due to the antiviral effects of both CAMs and C15, we also explored synergies between
these drugs. Rather than the full dose (20 molecules) for one of the drugs in isolation, as
in Figure 5a,b, administering a lower dose of both (six molecules for each) achieves the
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same result (Figure 5d), suggesting a synergistic effect. In contrast, combinations of CAMs
and PS-targeting drugs with other drug options, such as IFN, Tenofovir, release inhibitors,
and siRNAs, did not show any significant synergistic effects. Supplementary Figure S12
shows that the impact of treatment starts at different times post-infection, indicating that
nucleocapsid assembly inhibitors (CAM and C15) consistently perform better than other
treatment options and exhibit synergistic effects between them.
cccDNA is an important marker of chronic liver disease caused by HBV. To compute
the probability of cccDNA formation after viral entry in the drug-free case, we focused on
the reactions of the cccDNA formation step (Step 1; Figure 1), which are rcDNA delivery
to the nucleus (with rate α) and rcDNA conversion into cccDNA (with rate a). We did
10,000 simulations on this set of reactions for each value of α and a when one rcNC had
entered the cell.Figure 4b shows the number of simulations out of 10,000 in which the
cccDNA was not formed as a function of α and a. This figure indicates that, whilst the
rcDNA conversion rate to cccDNA (a) has only minimal impact on cccDNA formation,
the impact of the delivery rate of rcDNA to the nucleus (α) is significant for the outcome.
CAMs can bind to, and thus disassemble, the nucleocapsid after cell entry before delivery
of the rcDNA to the nucleus, thus reducing α. In particular, the disassembly rate (kdis) has a
significant impact on the prevention of cccDNA formation (Figure 5c). Figure 5c is plotted
similarly to Figure 4b, but in the presence of CAMs. By contrast, using anti-host DNA
factors (DDs) has minimal impact on the production of cccDNA unless they have almost
unrealistically small Kd (Kd < 1 nM; Supplementary Figure S6), and they are therefore not
likely to be as effective as CAMs in preventing cccDNA production. CAMs are therefore
more promising routes to therapy than the DDs that are currently being discussed as
possible therapeutic strategies.
4. Discussion
The in silico model of intracellular HBV infection dynamics introduced here is the most
comprehensive model to date and contains reactions for all pathways targeted by either
available anti-HBV drugs, or by proposed novel antiviral strategies that are alternative
options. It therefore lends itself for a comparative analysis of different therapeutic strategies
and can inform potential synergies.
Assessment of the impacts of different antiviral strategies [3,7] reveals that nucleo-
capsid assembly inhibitors, such as CAMs and PS-targeting drugs, are more promising
than other treatment options. Interestingly, we observed a strong synergistic effect between
CAMs and PS-targeting drugs, whilst other treatment options do not show comparable
synergistic effects with nucleocapsid assembly inhibitors. This suggests that nucleocapsid
assembly is a promising drug target, and could play an important role in achieving the
World Health Organisation’s (WHO’s) goal of eliminating HBV by 2030 [3].
The presence of cccDNA is a marker of HBV infection and a target of curative strategies.
We explored the consequences of therapeutic interventions preventing the formation of
new cccDNA in the context of our model. Our results suggest that strategies targeting
the delivery of the rcDNA into the nucleus are more effective than those targeting the
conversion of rcDNA into cccDNA. Our model also reveals that Geldanamycin (GA),
which targets the start of virion assembly (Step 5; Figure 1), is not a promising strategy
because the total number of virions released can increase in the serum, despite initial delays
in virion release. Similarly, our model demonstrates that targeting the HBx protein that
promotes cccDNA activation and blocks its silencing (Step 2; Figure 1) does not perform as
well as other drug strategies. It thus delivers a platform with which to assess the relative
potential of different antiviral strategies and provides a pointer towards the most promising
options for experimental development.
In contrast to continuous models, our discrete stochastic model permits tracking of
particles at low concentrations during the kinetic phase, providing unprecedented insights
into the production of different particle types at the early stages of an infection. In addition,
this model revealed a previously unrecognised two-phase behaviour in the release of spher-
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ical SVPs. We established that it occurs for all biologically relevant conditions, suggesting
that it is a biologically meaningful phenomenon. It is possible that the occurrence of high
levels of spherical SVPs at the very start of an infection and again in a second phase after
virion release has stalled could have consequences for the immune response. Our model
provides the foundation for studying such aspects of infection dynamics by coupling the
intracellular with an intercellular model in a multiscale approach. For parameters that were
not measured in vivo, we used estimates based on in vitro studies and other arguments, as
outlined in Table S1 and Section S3 in the Supplementary Material. Once such parameters
become available, they can be used to improve the predictive power of the model. In any
case, our intracellular model provides the first step in developing a multiscale within-host
model to understand the immune response to HBV infections.
Supplementary Materials: The following are available online at https://www.mdpi.com/1999-491
5/13/1/11/s1, Figure S1: The number of ribosomes (rib) plays an important role in the dynamics of
the model, Figure S2: If the parameter has a biologically relevant value, Figure S3: The binding rate
of RNA Pol II to cccDNA does not have any impacts on the dynamics of the model, Figure S4: The
probability of prevention of cccDNA formation with anti-host DNA repairfactors as a function of
the parameter a and the binding anity (Kd) of this drug, Figure S5: The number of complete virions
released with RNA interference treatment and parameter values from Table S1 as a function of the
binding anity (Kd) and the cleaving rate (kcleave) of this drug, Figure S6: The number of complete
virions released with CAM treatment and parameter values from Table S1, Figure S7: The number of
complete virions released with parameter values from Table S1, Figure S8: The average of cumulative
populations of proteins inside the cell over 100 simulations, Figure S9: The dynamics of incomplete
particles released with different treatment options after cccDNA formation, Figure S10: The number
of complete virions released with starting treatment at different times post-infection and parameter
values from Table S1, Figure S11: The HBV life cycle. Step 0: Viral entry is mediated by the sodium-
taurocholate co-transporting polypeptide (NTCP) receptor, Figure S12: Current and potential future
drugs for the treatment of HBV. Table S1: Table of parameter values, Table S2: Table of dissociation
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